Drug intelligence / Profile preview

netoglitazone

Development stage: Preclinical
Lead developer: Mitsubishi Tanabe Pharma
Modality: Small Molecules
Administration: Oral

Overview

Netoglitazone (MCC-555) is an experimental hypoglycemic agent belonging to the thiazolidinedione class. It is a small molecule that acts as an insulin sensitizer and has been investigated for its potential use in treating type 2 diabetes mellitus. Like other thiazolidinediones, it is presumed to act primarily by activating peroxisome proliferator-activated receptor gamma (PPARγ), thereby modulating the transcription of genes involved in glucose and lipid metabolism[6]. Netoglitazone remains investigational and has not been approved for clinical use.

Other names: 5-({6-[(2-fluorophenyl)methoxy]naphthalen-2-yl}methyl)-1,3-thiazolidine-2,4-dione

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on netoglitazone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on netoglitazone.

Explore the full profile